Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811219 | 0.87 | TRPM8 (0.53) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL9762691 | 0.80 | NPSR1 (0.52) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL19778 | 0.78 | NPSR1 (0.70) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL812818 | 0.78 | NPSR1 (1.00) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL2449504 | 0.77 | NPSR1 (0.61) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| Hydrochloric Acid SCHEMBL5094831 | 0.76 | NPSR1 (0.67) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL2091516 | 0.76 | NPSR1 (0.67) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| Bromide SCHEMBL31210017 | 0.76 | NPSR1 (0.67) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL9001706 | 0.75 | NPSR1 (0.58) | NPSR1ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL8393641 | 0.75 | NPSR1 (0.46) | NPSR1ALDH1A1KMT2APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1044197-B1 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKYNE CARBOXAMIDES AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSANTS | ASTELLAS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | claimed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | claimed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | claimed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-5451588-A | Treatment of migraines | MERCK SHARP & DOHME LTD. (GB) | 1995-09-19 | — | — | US | claimed |
| EP-1473334-B1 | JET PRINTING INK AND METHOD OF INK JET PRINTING | FUJIFILM CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-7455959-B2 | Photographic element containing a speed-enhancing compound | EASTMAN KODAK COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080248433-A1 | PHOTOGRAPHIC ELEMENT CONTAINING A SPEED-ENHANCING COMPOUND | NPEC INC. | 2008-10-09 | — | — | US | disclosed |
| US-7354701-B2 | Photographic element with speed-enhancing compound | EASTMAN KODAK COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| US-5914403-A | NOVEL 4-((PYRIDINO-CARBONYL)AMINO)-2-(CARBOXYLIC ACID OR ESTER)-5,6,7,8-OPTIONALLY SUBSTITUTED QUINOLINE COMPOUNDS AS ANTICONVULSANTS | NICHOLS ALFRED C (US) | 1999-06-22 | — | — | US | disclosed |
| US-5783700-A | ANTICONVULSANTS, TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISEASES, ANTIISCHEMIC, INTERACT WITH N-METHYL-D-ASPARTATE (NMDA) RECEPTOR COMPLEX | NICHOLS ALFRED C (US) | 1998-07-21 | — | — | US | disclosed |
| US-5672466-A | DEVELOPING SILVER HALIDE PHOTOGRAPHIC LIGHT SENSITIVE MATERIAL IN PRESENCE OF CARBONYLHYDRAZONE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0731380-A1 | Method for forming an image and silver halide photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | NPSR1 2343/4885ALDH1A1 1385/4885KMT2A 2179/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | NPSR1 159/4885ALDH1A1 1361/4885KMT2A 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.